文献类型：期刊文献

中文题名：新型冠状病毒肺炎诊治方案推荐医学观察期四种中成药对COVID-19的潜在共性机制分析

英文题名：Potential Common Mechanism of Four Chinese Patent Medicines Recommended by Diagnosis and Treatment Protocol for COVID-19(Trial Version 7)in Medical Observation Period

作者：曹如冰[1];马清林[1];徐倩娟[1];段海婧[1,2];杜丽东[1,2];宁艳梅[1,2];任远[1,2]

第一作者：曹如冰

机构：[1]甘肃中医药大学药学院,兰州730000;[2]甘肃省中药药理与毒理学重点实验室,兰州730000

第一机构：甘肃中医药大学药学院（西北中藏药协同创新中心办公室）

年份：2020

卷号：36

期号：4

起止页码：2

中文期刊名：中药药理与临床

外文期刊名：Pharmacology and Clinics of Chinese Materia Medica

收录：北大核心:【北大核心2017】；CSCD:【CSCD2019_2020】；

基金：甘肃省中药药理与毒理学重点实验室抗新型冠状肺炎专项基金(编号:2020-KXG-001)。

语种：中文

中文关键词：新型冠状病毒肺炎(COVID-19);新型冠状病毒诊疗方案;推荐中成药;网络药理学;共性机制

外文关键词：COVID-19;Diagnosis and Treatment Protocol for COVID-19(Trial Version 7);Recommended Chinese patent medicine;Network Pharmacology;Common mechanism of action

摘要：目的:运用网络药理学方法对《新型冠状病毒感染的肺炎诊疗方案(试行第7版)》中推荐的医学观察期四种口服中成药对新型冠状病毒肺炎(COVID-19)的潜在共性作用机制进行探讨,为防治新型冠状病毒肺炎提供参考。方法:通过TCMSP、pharmGKB、GeneCards、Uniprot数据库筛选藿香正气胶囊(丸、水、口服液)、金花清感颗粒、连花清瘟胶囊(颗粒)、疏风解毒胶囊(颗粒)中组方药物化学成分作用靶点和COVID-19相关靶点,采用omicshare平台对药物靶点和疾病靶点进行匹配映射,通过String数据库构建蛋白互作网络,应用Cytoscape软件构建上述中成药对COVID-19的"成分-靶点-疾病"交互网络图,利用DAVID数据库进行生物过程和通路进行注释,分析藿香正气胶囊(丸、水、口服液)、金花清感颗粒、连花清瘟胶囊(颗粒)、疏风解毒胶囊(颗粒)四种中成药对COVID-19可能存在的共有靶点和机制。结果:上述四种中成药与COVID-19有关的潜在共有作用靶点55个,与靶点相关的共有成分97个,相关生物过程44个、信号调控通路179条;CASP3、TP53、IL-10、TNF、IL-6、CXCL8、CCL2、MAPK8、FOS、MAPK1等靶点可能是上述四个中成药对COVID-19的潜在重要共性靶点,这些靶点与IL-17、TNF、C型凝集素受体等信号调控通路和脂多糖反应、细菌分子反应、细胞因子刺激反应等多个生物过程有关;槲皮素、木犀草素、汉黄芩素、β-谷甾醇、山柰酚、甘草查尔酮A、柚皮素等成分可能是上述四个中成药发挥潜在作用的重要共性成分。结论:藿香正气胶囊(丸、水、口服液)、金花清感颗粒、连花清瘟胶囊(颗粒)、疏风解毒胶囊(颗粒)对COVID-19可能有潜在的共性作用机制和共性成分;这些共有化学成分多为黄酮类化合物,提示黄酮类化合物对COVID-19可能具有重要的作用。
Objective:To explore the potential common mechanism of four Chinese patent medicines recommended by Diagnosis and Treatment Protocol for COVID-19(Trial Version 7)by network pharmacology and to provide the reference for prevention and treatment of COVID-19.Methods:The chemical component targets and COVID-19 related targets of Huoxiangzhengqi capsules(pills,water,oral liquid),Jinhuaqinggan granules,Lianhuaqingwen capsules(granules)and Shufengjiedu capsule(granule)were screened through TCMSP,pharmGKB,GeneCards,Uniprot database.Drug targets and disease targets were match mapping by Omicshare platform,the protein interaction network was constructed by String database.The component-target-disease network of COVID-19 was constructed by Cytoscape.GO analysis and KEGG enrichment analysis was conducted by David database.The possible common targets and mechanisms of four Chinese patent medicines against COVID-19 were analyzed.Results:A total of 55 potential generic targets,97 related components,44 related biological processes and 179 signaling pathways were obtained.CASP3,TP53,IL10,TNF,IL6,CXCL8,CCL2,MAPK8,FOS and MAPK1 targets may be important potential common targets of the above four Chinese patent drugs for COVID-19.These targets were related to signaling regulatory pathways such as IL-17,TNF,and c-type lectin receptors,as well as multiple biological processes such as the response to lipopolysaccharide,the response to molecule of bacterial origin and cellular response to cytokine stimulus.Ingredients such as Quercetin,luteolin,wogonin,beta-sitosterol,kaempferol,licochalcone-A and naringenin may be important common components with potential effects.Conclusion:Huoxiangzhengqi capsules(pills,water,oral liquid),Jinhuaqinggan granules,Lianhuaqingwen capsules(granules)and Shufengjiedu capsule(granules)have the common mechanism of action and common ingredients in the treatment of COVID-19.Most of these common chemicals are flavonoids.The result suggests that flavonoids may play an important role in COVID-19.